Adelle S. Jee

Adelle S. Jee

Auto-generated profile, based on publicly available information

Adelle S. Jee

Royal Prince Alfred Hosp, Dept Resp & Sleep Med, Sydney, NSW, Australia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2020 in Respirology
Verified
Journal Article
Open access
PDF file
AJAdelle S. Jee
Adelle S. Jee
RSRobert Sheehy
Robert Sheehy
PHPeter Hopkins
Peter Hopkins
TCTamera J. Corte
Tamera J. Corte
CGChristopher Grainge
Christopher Grainge
GKGregory J. Keir
Gregory J. Keir
Pulmonary complications in CTD are common and can involve the interstitium, airways, pleura and pulmonary vasculature. ILD can occur in all CTD (CTD‐ILD), and may vary from limited, non‐progressive lung involvement, to fulminant, life‐threatening disease. Given the potential for major adverse outcomes in CTD‐ILD, accurate diagnosis, assessment and careful consideration of therapeutic intervention are a priority. Limited data are available to guide management decisions in CTD‐ILD. Autoimmune‐mediated pulmonary inflammation is considered a key pathobiological pathway in these disorders, and immunosuppressive therapy is generally regarded the cornerstone of treatment for severe and/or progressive CTD‐ILD. However, the natural history of CTD‐ILD in individual patients can be difficult to predict, and deciding who to treat, when and with what agent can be challenging. Establishing realistic therapeutic goals from both the patient and clinician perspective requires considerable expertise. The document aims to provide a framework for clinicians to aid in the assessment and management of ILD in the major CTD. A suggested approach to diagnosis and monitoring of CTD‐ILD and, where available, evidence‐based, disease‐specific approaches to treatment have been provided.

1 October 2019 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
AJAdelle S. Jee
Adelle S. Jee
JSJoanne Sahhar
Joanne Sahhar
PYPeter Youssef
Peter Youssef
JBJane Bleasel
Jane Bleasel
SAStephen Adelstein
Stephen Adelstein
TCTamera J. Corte
Tamera J. Corte

15 May 2023 in Arthritis & Rheumatology
Verified
Journal Article
Open access
AJAdelle S. Jee
Adelle S. Jee
ISIain Stewart
Iain Stewart
PYPeter Youssef
Peter Youssef
SAStephen Adelstein
Stephen Adelstein
DLDonna Lai
Donna Lai
TCTamera J. Corte
Tamera J. Corte
Objective: In patients with systemic sclerosis (SSc), we investigated composite serum biomarker panels for the diagnosis and risk stratification of SSc–associated interstitial lung disease (SSc‐ILD).Methods: We analyzed 28 biomarkers in 640 participants: 259 patients with SSc‐ILD and 179 SSc patients without ILD (Australian Scleroderma Cohort Study), 172 patients with idiopathic pulmonary fibrosis (IPF‐controls) (Australian IPF Registry), and 30 healthy controls. A composite index was developed from biomarkers associated with ILD in multivariable analysis derived at empirical thresholds. We evaluated the performance of the index to identify ILD, and specifically SSc‐ILD, and its association with lung function, disease extent on radiography, and patient health–related quality of life in derivation and validation cohorts. Biomarkers to distinguish SSc‐ILD from IPF‐controls were identified.Results: A composite biomarker index, comprising surfactant protein D (SP‐D), Ca15‐3, and intercellular adhesion molecule 1 (ICAM‐1), was strongly associated with SSc‐ILD diagnosis, independent of age, sex, smoking history, and lung function (for biomarker index score 3, pooled adjusted odds ratio was 12.72 (95% confidence interval 4.59–35.21) (P < 0.001). The composite index strengthened the performance of individual biomarkers for SSc‐ILD identification. In SSc patients, a higher index was associated with worse baseline disease severity (for biomarker index score 3 relative to biomarker index score 0, the adjusted absolute change in forced vital capacity percent predicted was −17.84% and the diffusing capacity for carbon monoxide percent predicted was −20.16%; both P < 0.001).Conclusion: A composite serum biomarker index, comprising SP‐D, Ca15‐3, and ICAM‐1, may improve the identification and risk stratification of ILD in SSc patients at baseline.

9 August 2019 in Drugs
Verified
Journal Article
Closed access
AJAdelle S. Jee
Adelle S. Jee
TCTamera J. Corte
Tamera J. Corte

19 April 2021 in Respiration
Verified
Journal Article
Closed access
PDF file
AJAdelle S. Jee
Adelle S. Jee
MPMatthew J.S. Parker
Matthew J.S. Parker
JBJane F. Bleasel
Jane F. Bleasel
LTLauren K. Troy
Lauren K. Troy
ELEdmund M. Lau
Edmund M. Lau
TCTamera J. Corte
Tamera J. Corte
Background and objective: The research term “interstitial pneumonia with autoimmune features” (IPAF) encompasses interstitial lung disease (ILD) patients with autoimmune features not meeting diagnostic criteria for a defined connective tissue disease (CTD). It remains unclear if IPAF is a distinct disease entity with implications for management and prognosis. We describe an Australian IPAF population and compare their baseline characteristics and outcomes with distinct cohorts of idiopathic interstitial pneumonia (IIP), CTD-ILD, and unclassifiable ILD. Methods: Review of 291 consecutive patients attending a specialist ILD clinic was performed. Patients with a diagnosis of IIP, CTD-ILD, and unclassifiable ILD by ILD-multidisciplinary meeting (ILD-MDM) were included. Patients meeting the IPAF criteria were identified. Baseline clinical data, survival, and progression were compared between ILD groups. Results: 226 patients were included, 36 meeting the IPAF criteria. IPAF patients demonstrated a high prevalence of autoantibodies to tRNA synthetase (35.3%), Ro52 (27.8%), and neutrophilic cytoplasmic antigens (ANCA; 20.0%). IPAF and CTD-ILD patients demonstrated similar clinical characteristics (mean age 66.6 and 63.7 years, respectively, female predominant, frequent CTD-manifestations). Lung function did not differ between ILD groups. Disease severity, pulmonary hypertension (PH), and ILD-MDM diagnosis were strong predictors of worse transplant-free survival (TFS). Meeting the IPAF criteria was not associated with TFS. Conclusions: We identified IPAF as a heterogeneous phenotype that overlaps considerably with CTD-ILD. Disease severity, PH, and ILD-MDM diagnosis were more powerful predictors of survival outcomes than meeting the IPAF criteria.

1 October 2021 in Respiratory Medicine
Verified
Journal Article
Closed access
AJAdelle S. Jee
Adelle S. Jee
MPMatthew J.S. Parker
Matthew J.S. Parker
JBJane F. Bleasel
Jane F. Bleasel
LTLauren K Troy
Lauren K Troy
ELEdmund M. Lau
Edmund M. Lau
TCTamera J. Corte
Tamera J. Corte